Gynecologic Oncology

Toon Van Gorp, MD, PhD, discusses the efficacy of mirvetuximab soravtansine in FRα-positive platinum-resistant ovarian cancer after 30.5 months of follow-up.

The combination of zimberelimab and lenvatinib had antitumor activity and a manageable safety profile in pretreated advanced cervical cancer.

Olaparib maintenance following durvalumab plus chemotherapy improved PFS in different subgroups of pMMR endometrial cancer.

The addition of pembrolizumab to chemoradiotherapy prolonged survival and time to second progression in patients with locally advanced cervical cancer.

Cadonilimab plus lenvatinib showed promise as therapy for patients with advanced endometrial cancer and disease progression on prior platinum therapy.

Nivolumab elicited PR/CRs in all patients treated with resectable dMMR endometrial cancer and no patients experienced disease recurrence during follow-up.

All the data on the tumor-agnostic approvals of T-DXd and repotrectinib are featured in this article and it's downloadable PDF visual pages!

Treatment with pembrolizumab monotherapy was effective and well tolerated in pretreated patients with advanced clear cell gynecologic cancers.

A BLA has been accepted in China seeking the approval of tisotumab vedotin for metastatic cervical cancer that has progressed on or after systemic therapy.

Palbociclib plus letrozole prolonged PFS compared with placebo plus letrozole in patients with ER-positive advanced endometrial cancer.

Matthew Wagar, MD, discusses how the management of advanced and recurrent endometrial cancer has evolved in recent years.

Ritu Salani, MD, MBA, discusses considerations in clinical trial design and the evolving role of HER2-targeted ADCs in gynecologic malignancies.

Versamune HPV plus PDS01ADC and bintrafusp alfa demonstrated clinical benefit in locally advanced or metastatic HPV-associated cancers.

Matthew Wagar, MD, discusses treatment considerations for advanced/recurrent endometrial cancer.

Matthew Wagar, MD, discusses lenvatinib plus pembrolizumab vs chemotherapy as first-line treatment for advanced endometrial cancer.

Clinicians parse through the impacts of tumor-agnostic FDA approvals, examining T-DXd and repotrectinib's 2024 approvals in particular.

Emily M. Hinchcliff, MD, MPH, discusses how the addition of immunotherapy to chemotherapy has influenced the endometrial cancer treatment paradigm.

Bhavana Pothuri, MD, discusses the current treatment paradigm in endometrial cancer and the targeted therapies currently being investigated.

Matthew Wagar, MD, discusses the use of adjuvant immunotherapy in endometrial cancer and the importance of accurate staging in optimizing outcomes.

Experts provide insights on the 2024 FDA approvals in several different fields including solid tumors and more in this list featuring the regulatory decisions.

Ritu Salani, MD, MBA, details considerations for cervical cancer treatment as new approvals, research, and modalities affect several settings.

Short-course, higher dose vaginal brachytherapy for endometrial cancer had similar effectiveness to more frequent, lower dose sessions.

Pembrolizumab warrants further evaluation in patients with previously treated advanced clear cell gynecologic cancer in a randomized clinical trial.

The ACR-368 OncoSignature assay has received breakthrough device designation from the FDA for use in endometrial cancer.

Manish R. Patel, MD, and Gottfried E. Konecny, MD, detail findings from studies evaluating CLDN6-directed agents that showed signals of promising efficacy and tolerability.